<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382496</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-417</org_study_id>
    <nct_id>NCT03382496</nct_id>
  </id_info>
  <brief_title>Observational Study for Lung Cancer Patients Treated With Nivolumab</brief_title>
  <acronym>EVIDENS</acronym>
  <official_title>EVIDENS: Lung Cancer Patients TrEated With NiVolumab: A LongItuDinal, ProspEctive, ObservatioNal, Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will describe the characteristics of patients initiating nivolumab treatment for
      lung cancer and their outcomes over 3 years in France
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of gender</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of age</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of line of therapy at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of ECOG PS</measure>
    <time_frame>At baseline</time_frame>
    <description>Eastern Cooperative Oncology Group Performance Status (ECOG PS) A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of patients working status at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>QoL (EQ-5D) at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
    <description>Quality of Life (QoL) as assessed by European Quality of Life-5 Dimensions (EQ-5D) EQ-5D: the descriptive system consists of 5 dimensions: mobility, self-care, usual activities,pain/discomfort, and anxiety/depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median time from initial diagnosis to nivolumab initiation</measure>
    <time_frame>at baseline</time_frame>
    <description>Median time from initial diagnosis to nivolumab initiation (derived from date of initial diagnosis and date of first dose of nivolumab, assumed to be the date of D0 visit). Any lung cancer declaring more than 5 years after another cancer is defined as an initial diagnosis of lung cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients exposed to other lung cancer treatments</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of current smokers, former smokers, and non-smokers at initial diagnosis</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of cancer stage at initial diagnosis and at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of Lung cancer histology at initial diagnosis</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with untreated brain metastasis at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treated brain metastasis at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with PD-L1 expression at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
    <description>PD-LI (Programmed death-ligand 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with mutations at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of concomitant diseases at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with corticosteroids treatment at nivolumab initiation</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(OS) Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from index date (treatment with nivolumab) until date of death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival after initiation of nivolumab</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of nivolumab adverse drug reaction</measure>
    <time_frame>At 3 years after nivolumab initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 3 years after nivolumab initiation</time_frame>
    <description>PFS measured by time since index date (initial treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first as assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3 years after nivolumab initiation</time_frame>
    <description>ORR is measured by the sum of partial responses plus complete responses as assessed by (RECIST 1.1) Response Evaluation Criteria In Solid Tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Baseline to 3 years after nivolumab initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of patient management treatment patterns</measure>
    <time_frame>Baseline to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean weight change in kilogram from baseline</measure>
    <time_frame>Baseline up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean ECOG PS change from baseline</measure>
    <time_frame>Baseline up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of patients with new metastasis</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of patients with progression of pre-existing sites</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1462</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Lung Cancer patients in France</arm_group_label>
    <description>Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Lung Cancer patients in France</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study aims to collect data for patients diagnosed with a lung cancer and initiating
        nivolumab in France
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female: 18 age at the time of nivolumab initiation

          -  Pathologically confirmed diagnosis of lung cancer

          -  Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken
             by the physician prior to enrolling a patient in the study

        Exclusion Criteria:

        -Patient taking part in an interventional study for lung cancer treatment for which
        nivolumab is 1 of the investigational drugs

        Other protocol defined inclusion or exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fontaine Les Dijon</city>
        <zip>21121</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

